GLUE as reported
Monte Rosa Therapeutics, Inc. reported $29M of revenue over the trailing twelve months, −84% on the year before. 8 reported series are charted on this page, each one as filed.
$29M
Revenue, trailing twelve months · to Q2 2026 · −84% against the twelve months before
- Net Income
- −$161M
Net Income · −767% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$32M
Free Cash Flow · −234% year on year · trailing twelve months to Q2 2026
- Op Margin
- −946%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $29M | −84% | Q2 2026 |
| Net Income | −$161M | −767% | Q2 2026 |
| EPS | −$1.76 | −589% | Q2 2026 |
| Op Margin | −946% | n/a | Q2 2026 |
| Net Margin | −853% | n/a | Q2 2026 |
| ROE | −17% | n/a | Q2 2026 |
| ROA | −11% | n/a | Q2 2026 |
| Free Cash Flow | −$32M | −234% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Monte Rosa Therapeutics, Inc. (GLUE) - Revenue & ProfitRevenue & ProfitMonte Rosa Therapeutics, Inc. (GLUE)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com